Last updated: Jul 11, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07357597 | 4 | An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. | Trop2 -- antibody-drug conjugate (datopotamab deruxtecan) with corticosteroid prophylaxis |
| NCT06780098 | 2 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | Unknown mechanism |
| NCT06066138 | 1 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | PD-L1 -- immune checkpoint inhibitor (atezolizumab) |
| NCT06695845 | 2 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | HER2 -- bispecific antibody |
| NCT07431827 | 3 | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) | KRAS G12C -- covalent inhibitor (calderasib) plus PD-1 blockade (pembrolizumab) |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 34 |
| Shanghai Pulmonary Hospital, Shanghai, China | 28 |
| Tianjin Medical University Cancer Institute and Hospital | 27 |
| Hunan Province Tumor Hospital | 23 |
| AstraZeneca | 22 |
Countries/regions with the most active trial sites for lung cancer (nsclc). A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 1, 2026 | NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | Indocyanine green -- fluorescent dye for surgical navigation |
| Nov 30, 2026 | NCT07579221 | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer | EZH2 + PRMT5 -- epigenetic enzyme inhibitors |
| Sep 14, 2026 | NCT07619599 | A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab | PD-1 -- antibody (immune checkpoint inhibitor) |
| Aug 1, 2026 | NCT07436858 | Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer | HER2 -- radiolabeled antibody for PET imaging (diagnostic antibody) |
| Aug 2026 | NCT07675876 | Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer | Mast cell stabilization -- inhibition of mast cell degranulation (mast cell stabilizer) |
| Jul 31, 2026 | NCT07617337 | AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer | ALK -- tyrosine kinase inhibitor (TKI) |
| Jul 28, 2026 | NCT07683832 | Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC | Tumor antigens -- personalized cancer vaccine |
| Jul 15, 2026 | NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | DNA methyltransferases -- epigenetic inhibitor (azacytidine) + PD-L1 -- immune checkpoint inhibitor (durvalumab) + platinum-based chemotherapy |
You've seen the lung cancer (nsclc) landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.